Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Offen

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Plos Currents|September 7, 2012
Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's diseaseOfer Sadan, Eldad Melamed, Daniel Offen
Stem Cells (Dayton, Ohio)|September 14, 2021
Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseasesShay Herman, Idan Fishel, Daniel Offen
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 27, 2003
Apoptosis and Parkinson's diseaseNirit Lev, Eldad Melamed, Daniel Offen
Expert Opinion on Biological Therapy|October 14, 2009
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseasesOfer Sadan, Eldad Melamed, Daniel Offen
Journal of Molecular Neuroscience : MN|June 8, 2011
Striatal microinjection of Sydenham chorea antibodies: using a rat model to examine the dopamine hypothesisHilla Ben-Pazi, Ofer Sadan, Daniel Offen
Current Pharmaceutical Design|October 5, 2006
Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current stateYossi Gilgun-Sherki, Eldad Melamed, Daniel Offen
Journal of Molecular Neuroscience : MN|November 9, 2010
The "dying-back" phenomenon of motor neurons in ALSMichal Dadon-Nachum, Eldad Melamed, Daniel Offen
Journal of Neurology|March 12, 2004
The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapyYossi Gilgun-Sherki, Eldad Melamed, Daniel Offen
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 17, 2024
Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse modelTalya Shacham, Daniel Offen, Gerardo Z Lederkremer
Journal of Molecular Neuroscience : MN|September 23, 2003
Antioxidant treatment in Alzheimer's disease: current stateYossi Gilgun-Sherki, Eldad Melamed, Daniel Offen
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Plos Currents|September 7, 2012
Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's diseaseOfer Sadan, Eldad Melamed, Daniel Offen
Stem Cells (Dayton, Ohio)|September 14, 2021
Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseasesShay Herman, Idan Fishel, Daniel Offen
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 27, 2003
Apoptosis and Parkinson's diseaseNirit Lev, Eldad Melamed, Daniel Offen
Expert Opinion on Biological Therapy|October 14, 2009
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseasesOfer Sadan, Eldad Melamed, Daniel Offen
Journal of Molecular Neuroscience : MN|June 8, 2011
Striatal microinjection of Sydenham chorea antibodies: using a rat model to examine the dopamine hypothesisHilla Ben-Pazi, Ofer Sadan, Daniel Offen
Current Pharmaceutical Design|October 5, 2006
Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current stateYossi Gilgun-Sherki, Eldad Melamed, Daniel Offen
Journal of Molecular Neuroscience : MN|November 9, 2010
The "dying-back" phenomenon of motor neurons in ALSMichal Dadon-Nachum, Eldad Melamed, Daniel Offen
Journal of Neurology|March 12, 2004
The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapyYossi Gilgun-Sherki, Eldad Melamed, Daniel Offen
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 17, 2024
Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse modelTalya Shacham, Daniel Offen, Gerardo Z Lederkremer
Journal of Molecular Neuroscience : MN|September 23, 2003
Antioxidant treatment in Alzheimer's disease: current stateYossi Gilgun-Sherki, Eldad Melamed, Daniel Offen
Pageof 14